Neil Bhola, Ph.D. - Publications

Affiliations: 
2009 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Pharmacology, Molecular Biology

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV and HPV head and neck squamous cell carcinoma to cisplatin. Oral Oncology. 95: 35-42. PMID 31345392 DOI: 10.1016/j.oraloncology.2019.05.028  0.48
2019 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Research. 79: 875. PMID 30770370 DOI: 10.1158/0008-5472.CAN-18-4087  0.48
2019 Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. The Journal of Experimental Medicine. PMID 30683736 DOI: 10.1084/jem.20181936  0.48
2018 Leonard B, Brand TM, O'Keefe RA, Lee E, Zang Y, Kemmer JD, Li H, Grandis JR, Bhola NE. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Research. PMID 29792310 DOI: 10.1158/0008-5472.CAN-18-0459  0.48
2018 Brand TM, Hartmann S, Bhola NE, Li H, Zang Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, et al. Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Research. PMID 29440171 DOI: 10.1158/0008-5472.CAN-17-1672  0.48
2017 Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine. 9. PMID 28566428 DOI: 10.1126/scitranslmed.aal5148  0.48
2016 Grandis JR, Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RC, Johnson DE. Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27986750 DOI: 10.1158/1078-0432.CCR-16-2203  0.48
2016 Bhola NE, Johnson DE, Grandis JR. A sensible approach to targeting STAT3-mediated transcription. Annals of Translational Medicine. 4: S57. PMID 27868025 DOI: 10.21037/atm.2016.10.51  0.48
2016 Hartmann S, Bhola NE, Grandis JR. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27370607 DOI: 10.1158/1078-0432.CCR-16-0951  0.48
2015 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population. Cancer Research. PMID 26676751 DOI: 10.1158/0008-5472.CAN-15-1640-T  0.32
2015 Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Letters. PMID 26235139 DOI: 10.1016/j.canlet.2015.07.032  0.32
2015 Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/mcp.M115.049783  0.32
2015 Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Research. 75: 405-14. PMID 25480943 DOI: 10.1158/0008-5472.CAN-14-2475  0.32
2013 Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. The Journal of Clinical Investigation. 123: 1348-58. PMID 23391723 DOI: 10.1172/JCI65416  0.32
2013 Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Research. 73: 1190-200. PMID 23204226 DOI: 10.1158/0008-5472.CAN-12-2440  0.32
2012 Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine. 18: 1052-9. PMID 22683778 DOI: 10.1038/nm.2795  0.32
2012 Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Molecular Cancer Therapeutics. 11: 1236-46. PMID 22491800 DOI: 10.1158/1535-7163.MCT-11-0936  0.48
2011 Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4996-5004. PMID 21653688 DOI: 10.1158/1078-0432.CCR-10-3406  0.48
2010 Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. Journal of Proteome Research. 9: 3073-82. PMID 20426488 DOI: 10.1021/pr901211j  0.32
2010 Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2571-9. PMID 20388852 DOI: 10.1158/1078-0432.CCR-10-0333  0.32
2008 Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Molecular Cancer Research : McR. 6: 1946-56. PMID 19074839 DOI: 10.1158/1541-7786.MCR-07-2197  0.48
2008 Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Frontiers in Bioscience : a Journal and Virtual Library. 13: 1857-65. PMID 17981673  0.48
2007 Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular Cancer Therapeutics. 6: 1414-24. PMID 17431120 DOI: 10.1158/1535-7163.MCT-06-0678  0.48
2006 Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Research. 66: 11831-9. PMID 17178880 DOI: 10.1158/0008-5472.CAN-06-2876  0.48
Show low-probability matches.